AI and Genetic Engineering Drive Advances in Age Reversal Therapies
Recent developments in the field of longevity research highlight the potential of artificial intelligence (AI) and genetic engineering to significantly extend human lifespan. Harvard geneticist David Sinclair has been at the forefront of this research, suggesting that aging is a loss of information rather than function, which can be addressed through techniques like epigenetic reprogramming. AI is accelerating these advancements by enabling rapid simulation and screening of molecules that can reverse aging at the cellular level. Companies like Celularity are also exploring immune reinforcement by using natural killer cells to bolster aging immune systems. The introduction of senolytics, drugs that clear senescent 'zombie' cells, is another promising development. These efforts are supported by significant investments from tech billionaires and initiatives like the XPRIZE Healthspan competition, which aims to extend healthy human life by decades. 
